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In 2006, we demonstrated that mature somatic cells can be reprogrammed to a pluripotent state by gene transfer,
generating induced pluripotent stem (iPS) cells. Since that time, there has been an enormous increase in interest
regarding the application of iPS cell technologies to medical science, in particular for regenerative medicine and
human disease modeling. In this review article, we outline the current status of applications of iPS technology to
cell therapies (particularly for spinal cord injury), as well as neurological disease-specific iPS cell research (particularly
for Parkinson’s disease and Alzheimer’s disease). Finally, future directions of iPS cell research are discussed including
a) development of an accurate assay system for disease-associated phenotypes, b) demonstration of causative
relationships between genotypes and phenotypes by genome editing, c) application to sporadic and common
diseases, and d) application to preemptive medicine.
Keywords: Induced pluripotent stem cell, Cell transplantation, Spinal cord injury, Modeling human diseases,
Parkinson’s disease, Alzheimer’s diseaseThe development of induced pluripotent stem
(iPS) cell technologies and their significance
The 2012 Nobel Prize in Physiology or Medicine was
awarded for “The discovery that mature cells can be
reprogrammed to become pluripotent.” First, we would
like to consider the significance of this research. The
lives of mammals, including humans, begin with the
fertilization of an egg by a sperm cell. In humans, a blasto-
cyst composed of 70-100 cells forms by approximately 5.5
days after fertilization. The blastocyst is composed of the
inner cell mass, the cell population that has the ability to
differentiate into the various cells that constitute the body
(pluripotency), and the trophoblast, the cells that develop
into the placenta and extra-embryonic tissues and do
not contribute cells to the body. In the embryonic stage,
the pluripotent cells of the inner cell mass differentiate
into the three germ layers, endoderm, mesoderm, and
ectoderm, which will form specific organs and tissues
containing somatic stem cells with limited differentiation
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article, unless otherwise stated.differentiate, and, by adulthood, an individual composed
of 60 trillion cells is produced. Somatic stem cells born in
the fetal period actively divide, and are involved in the for-
mation and growth of various organs. However, even in
the adult, somatic stem cells persist in niches in every
organ and tissue, and play an important role in maintain-
ing organ and tissue homeostasis. When cells in the inner
cell mass are removed at the blastocyst stage and cultured
in vitro, pluripotent embryonic stem (ES) cells are ob-
tained. Thus, in the normal process of development, cell
differentiation of the three germ layers proceeds from
the simple stages of the fertilized egg and blastocyst,
and ultimately produces an individual consisting of a
complex cellular society.
In 1893, August Weismann argued that only germ cells
(eggs and spermatozoa) maintain a “determinant,” which
was described as heritable information essential to decide
on the functions and features of all somatic cells in the
body [1]. In his germ plasm theory, the determinants are
lost or irreversibly inactivated in differentiated somatic
cells.
It took more than 50 years for researchers to rewrite
this dogma. In 1962, Sir John Gurdon demonstrated the
acquisition of pluripotency by reprogramming cells to
their initial stage using a novel research technique, i.e.,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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nuclei into eggs [2]. However, for many years, that result
was regarded as a special case limited to frogs alone.
The production of Dolly the sheep by transferring the
nucleus of a somatic cell (mammary gland epithelial cell)
by Sir Ian Wilmut in the late 1990s [3] showed that
cloning could also be applied to mammals.
These brilliant previous works led to our studies that
culminated in the induction of pluripotency in mouse
somatic cells in 2006, using retroviral vectors to intro-
duce four genes that encode transcription factors i.e.,
Oct4, Sox2, Klf4, and c-Myc. We designated these cells
as iPS cells [4]. In 2007, we succeeded in generating
human iPS cells using genes encoding the same four
transcription factors [1]. The results of this research
showed that although the developmental process was
thought to be irreversible, by introducing key genes into
differentiated adult cells the cells could be reset to a
state in the extremely early stage of development in
which they possessed pluripotency. That is, the results
demonstrated that the differentiation process was revers-
ible. This startling discovery made it necessary to rewrite
the embryology textbooks.
Three major lines of research led us to the production
of iPS cells [5] (Figure 1). The first, as described above,
was nuclear reprogramming initiated by Sir John Gurdon
in his research of cloning frogs by nuclear transfer in 1962
[2] and by Sir Ian Wilmut, who cloned a mammal for the
first time in 1997 [3]. In addition, Takashi Tada showed
that mouse ES cells contain factors that induce repro-
gramming in 2001 [6]. The second line of research was
factor-mediated cell fate conversion, initiated by Harold
Weintraub, who showed that fibroblasts can be converted


















Figure 1 The history of investigations of cellular reprogramming that
2006 [4] became possible due to three scientific lines of investigation: 1) nu
3) ES cells. See the text for details (modified from Reference [5] with permigene, which encodes a muscle lineage-specific basic helix-
loop-helix transcription factor in 1987 [7]. The third line
of research was the development of mouse ES cells, ini-
tiated by Sir Martin Evans and Gail Martin in 1981
[8,9]. Austin Smith established culture conditions for
mouse ES cells and identified many factors essential for
pluripotency including leukemia inhibitory factor (LIF)
in 1988 [10]. Later, he developed the method to induce
the ground state of mouse ES cell self-renewal using
inhibitors for mitogen-activated protein kinase and
glycogen synthase kinase 3 [11], which supports the es-
tablishment of fully reprogrammed mouse iPS cells.
Furthermore, James Thomson generated human ES cells
[12] and established their optimal culture conditions using
fibroblast growth factor-2 (FGF-2). Without these previ-
ous studies, we could never have generated iPS cells. Inter-
est rapidly escalated, and, in tandem with the birth of iPS
cell technology, pluripotency leapt into the mainstream of
life sciences research in the form of “reprogramming tech-
nology” [13]. However, there remain many unanswered
questions regarding reprogramming technology. What are
the reprogramming factors in the egg cytoplasm that are
active in cloning technology? What do they have in com-
mon with the factors required to establish iPS cells and
what are the differences? What kind of epigenetic changes
occur in association with the reprogramming?
Apart from basic research in embryology, broad inter-
est has been drawn to the following possible applications
of iPS cell research: (1) regenerative medicine, including
elucidating disease pathologies and drug discovery re-
search using iPS cell disease models, and (2) medical
treatments (Figure 2). In this review, we describe these
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Figure 2 The application of iPS cell technologies to medical
science. iPS cell technologies can be used for medical science
including 1) cell therapies and 2) disease modeling or drug
development. See the text for details.
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regenerative medicine
General statement of iPS-based cell therapy
iPS cells can be prepared from patients themselves and
therefore great expectations have been placed on iPS cell
technology because regenerative medicine can be imple-
mented in the form of autografts presumably without
any graft rejection reactions. Although there have been
some controversies [14], the immunogenicity of termin-
ally differentiated cells derived from iPS cells can be
negligible [15-17]. Moreover, there has been substantial
interest in the possibility of regenerative medicine with-
out using the patient’s own cells; that is, using iPS cell
stocks that have been established from donor somatic
cells that are homozygous at the three major human
leukocyte antigen (HLA) gene loci and match theTable 1 Planned clinical trials of iPS cell-based therapies
Principal investigator (Institute/Location) Cell type to transplant
Masayo Takahashi, (RIKEN) Retinal Pigment Epithel
Alfred Lane, Anthony Oro, Marius Wernig
(Stanford University)
Keratinocytes
Mahendra Rao (NIH) DA neurons
Koji Eto (Kyoto University) Megakaryocyte
Jun Takahashi (Kyoto University) DA neurons
Steve Goldman, (University of Rochester) Oligodendrocyte precu
Hideyuki Okano, Masaya Nakamura (Keio University) Neural stem/progenitor
Shigeto Shimmura (Keio University) Corneal endothelial cel
Koji Nishida (Osaka University) Corneal epithelial cells
Yoshiki Sawa (Osaka University) Cardiomyocytes (sheet)
Keiichi Fukuda (Keio University) Cardiomyocytes (sphere
Yoshiki Sasai and Masayo Takahashi (RIKEN) Neuroretinal sheet inclu
cells
Advanced Cell Technology Megakaryocytes
Representative studies of iPS-based cell therapy with planned clinical trials are liste
References: [17,19-29].patient’s HLA type [18]. The development of regenera-
tive medicine using iPS cells is being pursued in Japan
and the USA for the treatment of patients with retinal
diseases, including age-related macular degeneration [19],
spinal cord injuries [17], Parkinson’s disease (PD) [20,21],
corneal diseases [22-24], myocardial infarction [25,26], dis-
eases that cause thrombocytopenia, including aplastic
anemia and leukemia [27,28], as well as diseases such as
multiple sclerosis (MS) and recessive dystrophic epider-
molysis bullosa [29] (Table 1).
Regenerative medicine research to discover a treatment
for spinal cord injury (SCI) by means of iPS cell
technologies
In 1998, Hideyuki Okano, in collaboration with Steven
Goldman, demonstrated for the first time the presence
of neural stem/progenitor cells (NS/PCs) in the adult
human brain using a neural stem cell marker, the ribo-
nucleic acid (RNA)-binding protein Musashi1 [30,31].
Research on nerve regeneration then commenced in
earnest. That same year, we began regenerative medicine
research on neural stem cell transplantation in a rat
model of SCI, and have since made progress in develop-
ing NS/PC transplantation therapies in experiments on
animal models of SCI. First, motor function was restored
by transplanting rat fetal central nervous system (CNS)-
derived NS/PCs into a rat SCI model [32]. The same
study also showed that the sub-acute phase is the opti-
mal time for NS/PC transplantation after SCI. In this
study, at least part of the putative mechanism by which
NS/PC transplantation restored function was identified
in animal models of SCI. Both the cell autonomousTarget disorders
ium (sheet) Age-related macular degeneration (wet type)
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neurons and host-derived neurons) and non-cell autono-
mous (trophic) effects mediated cytokines released from
the graft-derived cells are likely contributing to tissue re-
pair and functional recovery. Subsequently, a non-human
primate SCI model was developed using the common
marmoset, and motor function in that model was restored
by transplanting human fetal CNS-derived stem cells [33].
In the same study, a behavioral assay for motor function
associated with SCI was developed. Based on these stud-
ies, a preclinical research system for cell transplantation
therapy was established in a non-human primate SCI
model.
Given these findings, we began preparations for clinical
studies of human fetal CNS-derived NS/PC transplant-
ation to treat SCI patients. However, with the guidelines
for clinical research on human stem cells of the Japanese
Ministry of Health, Labor and Welfare that came into
effect in 2006, human fetus-derived cells and ES cells
became ineligible for use in regenerative medicine. Thus,
we had no choice but to change our strategy (human ES
cells became eligible for use in the 2013 guidelines). In
2006, one of our research groups (Yamanaka’s group)
established iPS cells from adult mouse skin cells. Hypothe-
sizing that it might be possible to induce NS/PCs from iPS
cells, we (Okano’s group) turned our attention to iPS cells
as a means of obtaining NS/PCs without using fetal or ES
cells. Based on conditions that were developed for experi-
ments on mouse ES cells [34,35], NS/PCs were induced
from mouse iPS cells [36]. The following year, we suc-
ceeded in restoring motor function by transplanting these
mouse iPS cell-derived NS/PCs into a mouse model of
SCI, and reported that when “good iPS cells” -derived NS/
PCs, which had been pre-evaluated as non-tumorigenic by
the transplantation into the brains of immunocomprom-
ised mice, were used for transplantation, motor function
was restored for a long period of time without tumors de-
veloping [37]. In 2011, we succeeded in restoring motor
function by transplanting human iPS cell-derived stem
cells into a mouse SCI model [38]. Moreover, in 2012,
motor function was restored by transplanting human iPS
(line 201B7) cell-derived NS/PCs into the marmoset
SCI model, and long-term motor function was recov-
ered without observable tumor formation [39]. This
finding was of great significance in terms of preclinical
research, and provided a proof of concept that could
potentially lead to a treatment method.
Collectively, when mouse or human iPS cells were in-
duced to form NS/PCs and were transplanted into mouse
or non-human primate SCI models, long-term restoration
of motor function was induced, without tumorigenicity, by
selecting a suitable iPS cell line [17,40]. Considering the
sub-acute phase (2-4 weeks after the injury) as the optimal
time for iPS cells-derived NS/PCs transplantation for SCIpatients, there are following major difficulties with
autograft-based cell therapy. First, it takes about a few
months to establish iPS cells. Second, it also takes three
months to induce them into NS/PCs in vitro. Third,
one more year would be required for the quality control
including their tumorigenesis.
Considering these, our collaborative team (Okano and
Yamanaka laboratories) are currently planning iPS-based
cell therapy for SCI patients in the sub-acute phase using
clinical-grade integration-free human iPS cell lines that
will be generated by Kyoto University’s Center for iPS Cell
Research and Application (CiRA). We will establish a pro-
duction method, as well as a storage and management sys-
tem, for human iPS cell-derived NS/PCs for use in clinical
research for spinal cord regeneration, build an iPS cell-
derived NS/PC stock for regenerative medicine, establish
safety screenings against post-transplantation neoplastic
transformation, and commence clinical research (Phase
I–IIa) trials for the treatment of sub-acute phase SCI
(Figure 3). As these studies progress, the application of
iPS cells to treat chronic phase SCI and stroke will be
investigated. Significant therapeutic efficacy in the treat-
ment of chronic phase SCI has not been achieved by cell
transplantation alone [41]. However, clinical studies are
planned using antagonists of axon growth inhibitors,
such as Semaphorin3A inhibitors [42], followed by
multidisciplinary rehabilitation combination therapies.
We aim to perform a clinical trial based on the Pharma-
ceutical Affairs Act in collaboration with drug companies
and to use iPS cell-derived NS/PC stocks for regenerative
medicine to establish treatment methods for stroke, MS,
and Huntington’s disease.
iPS cell technologies in nervous system disease
research
General statement of human disease modeling with iPS
cell technologies
Lesion sites are difficult to access in patients with degen-
erative diseases of the nervous system. Therefore, in past
studies, cell biological or biochemical analyses of their
pathology centered on forced expression of the causative
genes in non-nervous system cultured cell lines and on
mice in which the causative gene was knocked out. How-
ever, in a few instances, the animal or cell models did not
necessarily reflect the human pathology. Identifying cell
biological or biochemical changes in the initial stages of
the disease, before onset of symptoms, has been difficult
given analyses conducted on postmortem brains. However,
with the development of iPS cell technologies, it became
possible to establish pluripotent stem cells from the som-
atic cells of anyone, irrespective of race, genetic back-
ground, or whether the person exhibits disease symptoms.
Thus, it is no exaggeration to say that generation of
disease-specific iPS cells using iPS cell technologies is the
iPS cells
OCT3/4, SOX2, KLF4,
LIN28, p53 DN 
Preparation of clinical grade iPS-cell-derived NS/PCs stocks
(Okano Group in Keio University)
Neural differentiation and expansion of  iPS-derived NS/PCs  at the GMP level.
Quality control of clinical grade iPS-cell-derived NS/PCs.
Freeze and Stocks of clinical grade iPS-cell-derived NS/PCs.
L-MYC,
Figure 3 Strategies for the development of iPS cell-based cell therapy for SCI patients. Our collaborative team (Okano’s group at Keio
University and Yamanaka’s group at Kyoto University) have been developing an iPS cell-based cell therapy for SCI since 2006. Our previous
preclinical studies have shown that long-term functional restoration can be obtained by transplantation of NS/PCs derived from appropriate iPS
cells clones without observable tumor formation [10]. Currently, we aim to develop iPS cells-based cell therapy for SCI patients at sub-acute phase
using the clinical grade iPS cell-derived NS/PCs (i.e., the role of Okano’s group described in the blue box) which have been prepared from human
iPS cell stock (i.e., the role of Yamanaka’s group described in the yellow box).
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occur in patients in vivo, particularly for nervous system
disorders. The result has been a tremendous desire by
investigators who are conducting research on neurological
diseases to become engaged in disease-specific iPS cell
research [43-45].
A variety of disease-specific iPS cells have been used
to study nervous system diseases, including amyotrophic
lateral sclerosis (ALS) [46-48], spinal muscular atrophy
[49], spinobulbar muscular atrophy [50], Friedreich’s ataxia
[51], Alzheimer’s disease (AD) [52-54], PD [55-58],
Huntington’s disease [59,60], Machado-Joseph disease
[61], fragile X-syndrome [62], Rett’s syndrome [63],
familial dysautonomia (FD) [64], Pelizaeus-Merzbacher
disease [65], adrenoleukodystrophy [66], schizophrenia
[67-69], and Dravet’s syndrome of intractable epilepsy
[70-72] (Table 2). In the following sections, we describe
the results of nervous system disease-specific iPS cell
research using PD and AD as examples [44].
Modeling PD with disease-specific iPS cells
PD is the second most common neurodegenerative
disease after AD. More than 4 million patients are
afflicted with PD globally. In Japan, its prevalence is
about 100–150 cases per 0.5 million population [73].
PD is characterized by selective degeneration of dopa-
minergic (DA) neurons (A9 neurons) in the substantia
nigra, which results in motor symptoms, includingtremor, rigidity, akinesia, and postural instability. The
remarkable loss of neuromelanin-containing DA neurons
in the substantia nigra pars compacta and the appearance
of Lewy bodies (i.e., eosinophilic intracellular protein-
aceous inclusions) are characteristic of PD and related
diseases [74].
L-Dopa therapy or deep brain stimulation are current
methods of treating PD, but they are not curative treat-
ments. In most patients, the onset of PD occurs when
the person is in their late 60s to early 70s; therefore,
treatment of PD has become a major task in countries
facing an aging society. Based on previous research, mu-
tation of a specific gene is the cause of PD (familial PD
[FPD]) in approximately 10% of PD patients, whereas
the other 90% of patients have sporadic PD [73].
Interplay between genetic and environmental factors is
likely to play an important role in the pathogenesis of
PD. In human molecular genetic studies of rare mono-
genic forms of PD (FPD), at least 18 loci and 11 genes
leading to the development of FPD have been identified.
FPD-associated loci and genes for which there is conclu-
sive evidence of a role in the disease mechanism include
PARK1/PARK4 (α-synuclein [SNCA]), PARK2 (Parkin),
PARK6 (PTEN-induced kinase 1 [PINK-1]), PRAK7 (DJ-1),
PARK8 (leucine-rich repeat kinase 2 [LRRK2]), and PARK9
(ATPase type 13A [ATP13A2]). The gene products are
closely associated with the regulation of mitochondrial
function and oxidative stress. Environmental risk factors
Table 2 Representative reports on neurological/psychiatric disorders
Name of disease Gene responsible Cells responsible for pathogenesis References
Neurodevelopmental disorders
Rett syndrome MeCP2, CDK5L5 Neurons, neural precursors [63]
Spinomuscular atrophy SMN1 Motor neurons [49]
Familial dysautonomia IKBKAP Neural crest precursor cells [64]
Fragile X-syndrome FMR1 Neurons [62]
Adrenoleuko- dystrophy ABCD1 Oligodendrocytes [66]
Pelizaeus- Merzbacher disease PLP1 Oligodendrocytes [65]
Dravet syndrome SCN1A Neurons [70-72]
Late-onset neurodegenerative disorders
Alzheimer’s disease PS1, PS2, APP, sporadic Neurons [52,53,58,100]
Parkinson’s disease α-synuclein, PARKIN, PINK-1, LRRK2 etc. sporadic Dopaminergic neurons [55-59,83,87]
Amyotrophic lateral sclerosis SOD1, TDP43, FUS, C9ORF etc. sporadic Motor neurons, astroglia [47-49]
Spinobulbar muscular atrophy Androgen receptor Motor neurons, skeletal muscles [50]
Huntington’s disease HTT Glutamatergic neurons, GABAergic neurons [59,60]
Machado-Joseph disease ATX3 Glutamatergic neurons [61]
Psychiatric disorders
Schizophrenia 22q11.2, sporadic Glutamatergic neurons, GABAergic neurons,
dopaminergic neurons, etc.
[67-69]
Extracted and modified from References [43,44] and [73].
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pesticides, herbicides, and heavy metals (Fe, Cu, and
Zn). Furthermore, parkinsonism can be experimentally
induced by administration of certain drugs, including
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine),
which is metabolized to MPP+ in glial cells and blocks
mitochondrial functions. The mechanisms common to the
involvement of both genetic factors and environmental
factors in causing PD are mitochondrial dysfunctions and
increased oxidative stress [73]. Notably, there are close
associations between mitochondrial homeostatic mech-
anisms and the gene products encoded by the genetic
loci that are correlated with FPD. DA neurons are con-
stitutively exposed to oxidative stress, which damages
mitochondria and impairs membrane depolarization.
The lowered membrane potential of mitochondria leads
to stabilization of the protein kinase PINK1 (PARK6)
[75]. The stabilized PINK-1 then phosphorylates the
PARKIN protein (PARK2) (a member of the E3 ubiquitin
ligase family) [76-78] and recruits it from the cytoplasm to
the outer membrane of the mitochondria, where it ubiqui-
tinates mitochondrial outer membrane proteins, including
VDAC1 [79]. Mitochondrial outer membrane proteins
thus tagged are recognized by isolation membranes, which
then fuse with lysosomes and are ultimately degraded by
lysosomal enzymes. In addition, ATP13A2 (PARK9) [80] is
an H+-ATPase involved in lysosomal acidification, which
is necessary for lysosome function. Mitochondria damaged
by exposure to oxidative stress are degraded by mitophagy.The mutations in FPD result in impaired mitochondrial
homeostatic mechanisms. We have generated iPS cells
from FPD patients [58] to clarify the interaction between
impaired mitochondrial homeostatic mechanisms and the
development of PD. Okano’s group has established iPS
cells from cutaneous fibroblasts obtained from patients
with the PARK2 form of FPD (Patient A: female with an
exon 2–4 deletion mutation; Patient B: male with an exon
6–7 deletion mutation) by performing retroviral gene
transduction (Oct4, Sox2, Klf4, and c-Myc). After selecting
seven clones with good neuronal differentiation (PA1,
PA9, PA22, PB1, PB2, PB17, and PB20), NS/PCs and tyro-
sine hydroxylase (TH)-positive DA neurons were induced
from PARK2 patient-derived iPS cells and, as a control,
from human ES cells and healthy adult-derived iPS
cells. In investigating PARK2, patient-derived fibro-
blasts, iPS cells, NS/PCs, neurons, and DA neurons
were used to examine multiple aspects, including the
transcriptome, metabolome, proteome, and mitochondrial
homeostasis [58,73].
Increased oxidative stress is usually involved in the
pathogenesis of PD; therefore, oxidative stress was
measured in PARK2 iPS cell-derived neurons. These
cells exhibited increased oxidative stress accompanied
by activation of the Nrf2 pathway, which exerts a cytopro-
tective role under conditions of reactive oxygen species ac-
cumulation. A metabolome analysis of glycolytic pathways,
the tricarboxylic acid cycle, and pentose phosphate path-
ways suggested that mitochondrial were dysfunctional in
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Further characterization of mitochondria in the PARK2
iPS cell-derived neurons revealed abnormal mitochondrial
morphology and impaired mitochondrial turnover.
Lewy bodies, a pathology characteristic of PD, and
their main component, α-synuclein, were investigated in
PARK2 patient-derived iPS cells [58]. Based on an ana-
lysis of patient brain autopsies, Lewy bodies were found
to accumulate in the neurons of patients with sporadic
PD. However, while there have been several autopsy re-
ports for brains of PARK2 patients, α-synuclein was not
generally thought to accumulate in the brain in PARK2
FPD. When the postmortem brain of a PARK2 patient
was examined histologically, Lewy bodies and aggregates
of α-synuclein were confirmed, and examination of
neuronal cells derived from iPS cells of the same patient
revealed that α-synuclein had accumulated in a similar
manner [58]. These results were the first to demonstrate
that patient iPS cell-derived neuronal cells faithfully
reproduced a phenomenon that occurred in the brain of
the same patient.
There is growing interest in genome editing of human
iPS cells in introducing mutations into isogenic iPS cells
(reviewed in [81]) and in rescue experiments via genetic
repair, as methods to demonstrate genotype-phenotype
causal relationships in human genetic disorders (discussed
in iPS cell technologies in nervous system disease research
and Conclusion) (Figure 2). Various PD-associated ab-
normalities, including neurite outgrowth abnormalities,
DA neuron death induced by the addition of 6-
hydroxydopamine, tau and α-synuclein deposition, and
gene expression changes in DA neurons, have been ob-
served in DA neurons derived from iPS cells prepared
from a patient with a LRRK2 gene mutation (G2019S
mutation) and in isogenic control iPS cells in which the
G2019S mutation was introduced. These PD-associated
phenotypes were rescued by genetic correction of the
LRRK2 mutation in the patient-derived iPS cells [82].
Studies of PD using iPS cell technology have shown the
presence of PD-associated abnormalities in: 1) mitochon-
drial function, 2) the unfolded protein response and Golgi
to endoplasmic reticulum transport and 3) axonal trans-
port and cytoskeletal and neurite extension/retraction
responses (Courtesy of Dr. Ole Isacson, Harvard Medical
School). Thus, iPS-cell-based disease modeling is expected
to contribute to the elucidation of the pathophysiology of
PD, and be useful in drug screening and the development
of methods for extremely early diagnosis, before the
appearance of motor symptoms.
AD
AD accounts for approximately half of all cases of de-
mentia and is the most common intractable neurological
disease. AD is usually first manifested by a memorydisorder in a person aged 65 years or older. AD always
progresses to disorientation and a decreased ability to
comprehend and make judgments, and ultimately leads
to personality disorders and a bedfast state. In recent
years, early-onset AD, in which onset occurs from the
fifth decade of life onward, has also attracted attention.
People with early-onset AD lose the ability to conduct
their daily lives and need long-term care; therefore, this
disease has become a major social problem. Current
treatment is primarily symptomatic, and the development
of curative treatments has been slow. There are currently
no prospects for a complete cure [44].
Based on previous research, it is clear that large
amounts of amyloid beta (Aβ) accumulate in the brains
of AD patients and cause pathological changes called se-
nile plaques. Moreover, experiments conducted on cell
cultures and mice suggest that the highly toxic Aβ-42
may be overproduced in AD. The “amyloid hypothesis”,
which states that Aβ is the cause of the disease, has been
difficult to verify in living nerve cells of patients using
previous technologies. In collaboration with the Keio
University neurology department team (Drs. Takuya Yagi
and Daisuke Ito, Professor Norihiro Suzuki, and col-
leagues), we produced iPS cells from skin fibroblasts of
familial AD (FAD) patients (presenilin (PS)-1 or -2 muta-
tions) and succeeded in inducing neuronal cells for the
first time [52]. We confirmed that these patient-derived
neuronal cells produce twice the normal level of the
highly toxic Aβ-42. This result correlated with Aβ accu-
mulation in neural cells derived from living patients
with AD. In addition, we treated AD iPS cell-derived
neuronal cells with a γ-secretase modulator, which is a
candidate drug for the treatment of AD, and showed
that production of Aβ-42 was inhibited. Thus, these
disease-specific iPS cells enabled a novel drug to be
developed for the treatment of dementia [44].
In a study by Israel et al., Aβ accumulation in neural
cells induced from sporadic AD patient-derived iPS cells
[53] was similar to our finding showing that in neural
cells induced from FAD patient-derived iPS cells [52].
Accumulation of phosphorylated tau, in addition to Aβ,
was observed in the neurons induced from iPS cells of
one of the sporadic AD patients [53]. Gene analysis data
were not described in this report [53], but the phosphor-
ylated tau phenotype was not detected in FAD-derived
neurons that had a PS1 or PS2 gene mutation [52].
These observations are extremely interesting from the
standpoint of the diversity of AD phenotypes. Based on
these results, AD pathology can be detected in sporadic
AD, as well as FAD, and will lead to the development of
new treatments [44].
In addition, Dr. Haruhisa Inoue’s research group at
CiRA produced iPS cells from the skin cells of patients
with a mutation in the amyloid precursor protein (APP)
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AD, and from patients with late-onset (sporadic) AD
who had no family history of AD. The mutant APP iPS
cells were induced to differentiate into cerebral neurons.
When a mutation called APP-E693Δ was present, the Aβ
protein formed oligomers, accumulated in cells, induced
endoplasmic reticulum and oxidative stress, and caused
induction of the cell death gene Caspase4. Intracellular
stress and neuronal cell death were inhibited by the unsat-
urated fatty acid docosahexaenoic acid (DHA), which is
present at high levels in fish oils. Moreover, intracellular
Aβ oligomers and cell stress have also been observed in
some patients with late-onset sporadic AD, similar to
the APP-E693Δ cells. Based on the analysis of neurons
induced from iPS cells derived from several patients,
there is an AD population in which DHA is effective and
an AD population in which is it not. These findings sug-
gest a diversity of pathologies in AD and, correspondingly,
the need for a diversity of treatment strategies [44,54].
Monogenic FAD is rare in comparison to the sporadic
form. However, genetic predisposing factors, for example
ApoE, are present in sporadic AD. ApoE4 is the major
known genetic risk factor for AD. ApoE is one of the five
main types of blood lipoproteins (A-E) with 299 amino
acids, with three different isoforms (ApoE2 (Cys112,
Cys158), ApoE3 (Cys112, Arg158) and ApoE4 (Arg112,
Arg158)) [83]. Genetic polymorphism of the ApoE gene
is responsible for the generation of these isoforms [84].
While ApoE4 allele is found in approximately 14% of the
population [85], the ApoE4 allele is genetically associated
with late-onset familial and sporadic forms of AD [86],
highlighting the importance of ApoE4 in the pathogen-
esis of AD. In the future, the role of ApoE4 should be
characterized by a combination of iPS cell technologies
and genome editing.
Future tasks for iPS cell researchers with regard to
modeling human diseases
As described above, iPS cell researchers have developed
new strategies to study the pathophysiology of human dis-
eases and to provide assay systems for drug screening.
However, many tasks remain to be accomplished to enable
iPS cell technologies to accurately model human diseases
and to develop new therapeutic interventions.
a) Development of an accurate assay system for
disease-associated phenotypes
One of the problems with current iPS cell
technologies is that the somatic cells generated from
undifferentiated iPS cells remain immature for long
periods. As a result, iPS cell technologies have been
most successful in modeling pediatric or early-onset
diseases, including FD [64], epilepsy (e.g., Dravet
syndrome [70-72]), and Rett syndrome [63]. Apotential problem with current iPS cell technologies
in modeling late-onset neurodegenerative diseases is
the difficulty in obtaining age-related phenotypes in
a relatively short timeframe. Lorenz Studer’s group
recently succeeded in inducing rapid cell aging by
mis-expression of progerin, a truncated form of
lamin A that is associated with premature aging
[87]. This method made it possible to induce aging
in PD patient iPS cell-derived DA neurons that
resulted in disease-related phenotypes, including
severe dendrite degeneration, progressive loss of
TH-positive cells, and abnormal mitochondria or
Lewy body precursor-like inclusions, which are
difficult to identify using conventional neuronal
differentiation methods for iPS cells [87]. Notably,
we did not observe any Lewy bodies in DA neurons
induced from PD patient-derived iPS cells [58], even
though α-synuclein accumulated in progerin-
expressing DA neurons in vitro [87] and Lewy
bodies were prominent in the brain autopsy of the
patient [58]. Although α-synuclein is their major
component, Lewy bodies contain several other
components including neurofilaments and ubiquitin
[74,88,89]. These observations indicate that Lewy
body formation is a dystrophic age-related event,
and, thus, Lewy bodies may not form in DA neurons
induced from PD patient-derived iPS cells by
conventional culture methods. Thus, progerin-
induced aging is a versatile method to investigate the
features of late-onset age-related diseases by iPS
cell-based disease modeling, while their application
to other age-related diseases needs to be verified.
b) Demonstration of causative relationships between
genotypes and phenotypes by genome editing
As a result of the rapid progress in human genome
sequencing since the advent of next-generation
sequencers, enormous numbers of disease-related
mutations and single-nucleotide polymorphisms
(SNPs) have been identified. Heterogeneity in the
genetic mutations associated with some diseases is
common. In most diseases, there is no formal proof
of a causal relationship between the genetic
mutation and the disease phenotype because
experimental genetic studies are not possible in
humans, as opposed to animal models, such as
Drosophila and mouse. However, demonstration of a
causal relationship between a genetic mutation and a
disease phenotype can be verified using genome
editing technologies such as the helper-dependent
adenoviral vector [90], zinc-finger nucleases [91],
transcription activator-like effector nucleases [92,93],
or the CRISPR-Cas9 system [94,95] or its improved
method [96]. These technologies can be used to
perform rescue experiments with gene corrections,
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introducing disease-related mutations into control
iPS cells [82]. Thus, while genome editing is a
powerful technology for demonstrating genotype-
phenotype causal relationships, the current genome
editing techniques can only be applied to monogenic
disorders, and new technologies will need to be
developed to investigate polygenic disorders.
c) Application to sporadic and common diseases
Although Mendelian inheritance patterns have been
well documented in several neurodegenerative
diseases, including PD, AD, and ALS, the majority of
the cases of these diseases are sporadic, and the
genetic defects responsible for these cases remain to
be identified [97]. In Mendelian diseases, the effect
of genetic variation is extremely large, while the
allele frequency is extremely low. Thus, Mendelian
diseases are well suited for iPS cell-based disease
modeling and genome editing. By contrast, the
molecular etiology of most sporadic neurodegenerative
diseases remains unknown. In a series of studies of the
human genetics of sporadic diseases, genome-wide
association studies (GWAS) with SNPs have been
conducted as a means of identifying susceptibility
genes for sporadic neurodegenerative diseases.
Remarkably, these GWAS studies have succeeded in
identifying disease-related rare variants with a high
odds ratio [97]. For example, the glucocerebrosidase
(GBA) gene polymorphism was identified as a
robust genetic risk factor for PD [98]. It will be
important to characterize the role of GBA mutations
from the standpoint of the molecular etiology of
PD, using iPS cell-based in vitro characterization.
Since their effect size is not small, such sporadic
diseases with rare genetic variants are also likely to
be suitable targets for iPS cell-based disease modeling.
However, it will be important to establish iPS cells
from a sufficient number of patients and to
characterize a large number of clones to perform
statistical analyses. Therefore, it will be essential to
develop large-scale automated systems for the
production and differentiation of iPS cells.
d) Application to preemptive medicine
iPS cell-based disease modeling could play an
important role in the early diagnosis of late-onset
neurodegenerative diseases such as AD and PD.
Since the motor symptoms of PD do not develop
until almost 70% of the DA neurons in the substantia
nigra have been lost, the molecular mechanisms
that predominate during the initial stages of PD
remain unknown. However, studies characterizing
iPS cells derived from the somatic cells of PD
patients have provided an excellent opportunity and
excellent tools to investigate the course of changesduring PD, from the asymptomatic phases through
to the later stages when the pathology has become
prominent. Such studies could help to develop an
appropriate preemptive neuroprotective treatment
for PD, including small molecules, gene therapy, or
cell therapy, which could be started early in the
asymptomatic phase. AD usually has a long
progression of more than 30 years that consists of
an asymptomatic phase of ~20 years, a mild
cognitive impairment (MCI) phase of ~10 years,
and a dementia phase of unlimited length. Amyloid
plaques form and continue to enlarge in the
asymptomatic phase, and there is already substantial
neuronal loss and brain atrophy in the MCI phase
[99]. Thus, if diagnosis were possible in the
asymptomatic phase, it would provide a great
advantage by enabling the use of treatments to
prevent dementia, including γ-secretase modulators
[52], Non-Steroidal Anti-Inflammatory Drugs
(NSAIDs) [100], and DHA [54]. A combination of
iPS cell-based phenotypic screening, whole genome
sequencing by next-generation sequencing to
identify AD-related polymorphisms, and imaging of
Aβ and tau by positron emission tomography would
enable reliable diagnosis of AD in the asymptomatic
phase. While obtaining a proof of concept for such
preemptive treatments of AD would be difficult to
obtain in a short time, we hope that such data can
be obtained by using a combination of large-scale
iPS cell-based disease modeling and a cohort study
of dominantly inherited FAD, similar to the
Dominantly Inherited Alzheimer Network (DIAN)
study [101-103]. The development of preemptive
treatments for late-onset neurodegenerative
diseases would be enormously important in rapidly
aging countries like Japan.Conclusions
As described above, since 2006, there have been enormous
progresses in iPS cell technologies aiming for medical sci-
ence, in both regenerative medicine and human disease
modeling. Furthermore, iPS cell technologies could be ap-
plied for preemptive medicine. However, it is also true that
iPS cell technologies have not yet saved any patients’ lives
at this moment in early 2014. Continuous efforts through
the cooperation of basic stem cell biology, clinical investi-
gation of diseases, translational research, pharmaceutical
science, regulatory science and system biology will be ne-
cessary to let iPS cells really contribute to human health.
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